PMC:7600245 / 11363-11716 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T39","span":{"begin":135,"end":143},"obj":"Disease"}],"attributes":[{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T104","span":{"begin":29,"end":35},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T105","span":{"begin":37,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T105","span":{"begin":247,"end":257},"obj":"Chemical"},{"id":"T106","span":{"begin":258,"end":263},"obj":"Chemical"},{"id":"T107","span":{"begin":347,"end":352},"obj":"Chemical"}],"attributes":[{"id":"A105","pred":"chebi_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A106","pred":"chebi_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A107","pred":"chebi_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group."}

{"project":"LitCovid-sentences","denotations":[{"id":"T84","span":{"begin":0,"end":353},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group."}

{"project":"LitCovid-PubTator","denotations":[{"id":"291","span":{"begin":29,"end":35},"obj":"Species"},{"id":"303","span":{"begin":247,"end":257},"obj":"Chemical"},{"id":"318","span":{"begin":135,"end":143},"obj":"Disease"}],"attributes":[{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"Tax:9606"},{"id":"A303","pred":"tao:has_database_id","subj":"303","obj":"MESH:C000606551"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group."}